Home > Full Text Reviews > Angiotensin-Converting Enzyme Inhibitors... > Abstract and Full-Text Screening Criteria

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Jun. (Comparative Effectiveness Reviews, No. 34.)

Appendix CAbstract and Full-Text Screening Criteria

Abstract Screening Criteria

An abstract will be included if all of the following criteria apply:

An abstract will be excluded if any of the following criteria apply:

  • No patients have hypertension OR some patients have hypertension, but results not reported separately for this subgroup;
  • All subjects aged < 18 years OR some subjects aged < 18 years, but results not broken down by age;
  • Only comparison is an ACEI + an ARB versus placebo.

An abstract will be identified as a review if it is a relevant review article, meta-analysis, methods article, or cost-effectiveness analysis.

For each abstract, please mark either “EX” for Exclude, “IN” for Include or “Rev” for Review.

For included studies, please mark:

For all included studies, please also indicate the longest length (weeks or months) of followup.

Thus, coding for each abstract should be either:

  • EX
  • Rev
  • IN AcVAr (specify # weeks or # months followup, or write “NS” if length of followup not specified)
  • IN AcVR (specify # weeks or # months followup, or write “NS” if length of followup not specified)
  • IN ArVR (specify # weeks or # months followup, or write “NS” if length of followup not specified)
  • Info (if full-text needed to assess eligibility)

Full-Text Screening Criteria

Note: Screeners were instructed to work from top to bottom of the following list, choosing the first (if any) exclusion reason that applied.

  1. Condition of interest = essential hypertension

    Exclude if no patients have essential hypertension or if results not reported separately for subgroup with essential hypertension

  2. Population of interest = adults (≥ 18 years)

    Exclude if all subjects < 18 or if results not reported separately for ≥ 18 subgroup

  3. Interventions & comparators of interest:
    ACEIs, ARBs, and direct renin inhibitors listed at end of this document

    Include “grouped” comparisons, e.g., specific ARB vs. “ACE inhibitors” or unspecified “ARBs” vs. unspecified “ACEIs”

    Include ACEI + drug X vs. ARB + drug X (e.g., losartan + HCTZ vs. enalapril + HCTZ)

    Exclude ACEI + drug X vs. ARB + drug Y (e.g., enalapril + manidipine vs. irbesartan + HCTZ)

    Exclude if ACEI, ARB, or direct renin inhibitor not on lists at end of this document

  4. Study designs:

    Include all clinical study designs (RCTs, non-RCTs, cohorts, etc.); cross-sectional studies OK if time on treatment reported and ≥ 12 weeks

    Exclude if not clinical study (review, etc. – please specify)

  5. Outcomes of interest:
    For Key Question 1 and 3:

    Intermediate outcomes:

    Blood pressure control

    Rate of use of a single antihypertensive agent for blood pressure control

    Lipid levels

    Progression to type 2 diabetes

    Markers of carbohydrate metabolism/diabetes control (glycated hemoglobin [HbA1c], dosage of insulin or other diabetes medication, fasting plasma glucose, aggregated measures of serial glucose measurements)

    LV mass/function

    Creatinine/GFR

    Proteinuria

    Health outcomes:

    Mortality (all-cause, cardiovascular disease-specific, and cerebrovascular disease-specific)

    Morbidity (cardiac events (myocardial infarction, heart failure, cerebral vascular disease or events [including stroke], symptomatic coronary artery disease, end-stage renal disease, PVD [as clinically manifest, not markers of], quality of life)

    For Key Question 2 and 3:

    Safety (overall adverse events, withdrawals due to adverse events, serious adverse events reported, withdrawal rates, switch rates)

    Specific adverse events (including, but not limited to: weight gain, impaired renal function, angioedema, cough, hyperkalemia)

    Tolerability

  6. Persistence

  7. Adherence

  8. Sample size:

    We will not exclude articles based on sample size during the full text screening but may re-visit this decision when performing the full-text abstraction and synthesis.

  9. Treatment duration/length of followup:

    Exclude if treatment duration or longest followup < 12 weeks

  10. Included ACEIs
    Included ARBs
Cover of Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update
Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update [Internet].
Comparative Effectiveness Reviews, No. 34.
Sanders GD, Coeytaux R, Dolor RJ, et al.

AHRQ (US Agency for Healthcare Research and Quality)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...